Drug Development Pharma - February 5, 2014
SMEs drive behind innovative medicine
Over 40% of innovative medicines recommended for marketing authorisation in the European Union between 2010 and 2012 originated from small or medium-sized enterprises, says EMA. According to an article published recently in Nature Reviews Drug Discovery, authored by staff members of the European Medicines. Agency (EMA), small or medium-sized enterprises (SMEs), academia, public bodies and […]
Drug Development Pharma - January 31, 2014
AstraZeneca joins cancer consortium
Together with DKFZ and EORTC, AstraZeneca has joined the Worldwide Innovative Network (WIN) Consortium in personalized cancer medicine. WIN is a lobal network of academics, industries, payors and patient advocacy organizations which goal is to significantly improve survival and quality of life of cancer patients in the next three years. It was initiated in 2010 with leadership from the […]
Drug Development Pharma - January 30, 2014
AstraZeneca closes India R&D unit
The drug maker is to close its Avishkar R&D centre in Bangalore, India, and move parts of its research to Great Britain. The move that will impact 168 employees and early-stage research on tuberculosis and malaria. The decision to shut the R&D centre is said to be part of an ongoing global restructuring exercise. The pharmaceutical development […]
Drug Development Pharma - January 23, 2014
EU approval for new diabetes treatment
AstraZeneca and Bristol-Myers Squibb treatment for type 2 diabetes Xigduo has been granted Marketing Authorization by the European Commission. Xigduo, which has the trade name Forxiga, combines dapagliflozin, a selective and reversible inhibitor of SGLT2 with metformin hydrochloride, two anti-hyperglycaemic products with complementary mechanisms of action to improve glycaemic control. This is the first regulatory approval for a […]
Drug Development Pharma - January 22, 2014
Nuevolution enter drug discovery collaboration
The Institute of Cancer Research (ICR), London, Cancer Research Technology (CRT), London and Nuevolution, Copenhagen have entered into a drug discovery collaboration to identify novel lead candidates for cancer treatment. Researchers will use Nuevolution’s screening technology, Chemetics, to screen libraries each of millions of DNA-tagged compounds to identify those that act on a key protein in the stress […]
Drug Development Pharma - January 21, 2014
MVA Ambassador contributes to CBS report about pharmaceutical public-private partnering
MVA Ambassador Torsten Jepsen, responsible for the U.S. East Coast, played a key role in developing a new report by Copenhagen Business School (CBS), which examines the growing trend of pharmaceutical companies teaming up with universities to boost innovation and speed up drug discovery. The report, entitled “Value and growth through new kinds of innovative […]
